Elucid

Elucid is a Boston-based medical technology company founded in 2013 with the slogan "Bringing Imaging to Life." The company focuses on bringing histology-validated software to optimize treatment decisions for patients with cardiovascular disease. Elucid's advanced clinical insight, particularly through its CTA analysis, provides critical information for precision medicine and is the first non-invasive software to quantify atherosclerotic plaque characteristics compared to histopathology, including Lipid Rich Necrotic Core. Elucid has also published studies for its derivation of fractional flow reserve (FFRct) based on the vasodilative capacity of the vessel wall. The recent $80.00M Series C investment from Elevage Medical Technologies in 9 November 2023 underscores the confidence in Elucid's potential in addressing unmet needs in cardiovascular care. The company's focus on improving treatment decisions by physicians can lead to better patient outcomes, improved quality of care, and reduced healthcare costs. Elucid operates in the Analytics and Biotechnology industries.